NCT04221438 2026-04-01
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Phase 2 Terminated
Clinical Trials
13 trialsNCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT05260684 2025-03-06
OCEANMIST
Pfizer
Completed
NCT01436656 2024-10-28
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Pfizer
Phase 1 Completed
NCT03864042 2024-09-27
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01894672 2024-07-16
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05003622 2024-06-24
OCEANI
Pierre Fabre Medicament
Phase 1 Completed
NCT04655157 2024-05-23
QUAD01
University of Pittsburgh
Phase 1/2 Terminated
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT03911869 2023-05-31
POLARIS
Pfizer
Phase 2 Terminated
NCT01820364 2017-01-09
LOGIC
Array BioPharma
Phase 2 Terminated
NCT01777776 2016-09-13
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Array BioPharma
Phase 1/2 Terminated